Jpmorgan Chase & CO Evaxion Biotech A/S Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Dec 26, 2024
BUY
$0.6 - $1.17 $5,398 - $10,526
8,997 New
8,997 $6,000
Q4 2023

Feb 12, 2024
SELL
$0.6 - $1.17 $171 - $334
-286 Reduced 3.08%
8,997 $6,000
Q3 2023

Nov 14, 2023
SELL
$0.48 - $1.33 $9,538 - $26,428
-19,871 Reduced 68.16%
9,283 $7,000
Q2 2023

Aug 11, 2023
BUY
$1.12 - $1.74 $32,652 - $50,727
29,154 New
29,154 $38,000

Others Institutions Holding EVAX

# of Institutions
1
Shares Held
37.5K
Call Options Held
0
Put Options Held
0
View Full List

About Evaxion Biotech A/S

EVAX Quotes by TradingView
  • Ticker EVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,977,900
  • Market Cap $20.4M
  • Description
  • Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...
More about EVAX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email